The global AI in Drug Discovery Market is witnessing rapid growth, driven by the increasing integration of artificial intelligence technologies in pharmaceutical and biotechnology research. AI platforms are transforming drug discovery by enabling faster identification of novel drug candidates, biomarkers, and therapeutic targets, while optimizing clinical trial design and streamlining R&D processes. The market’s expansion is fueled by rising investments in pharma research, growing demand for personalized medicine, and the application of AI across oncology, neurology, infectious diseases, and rare disorders. As a result, AI is becoming a pivotal force in modern drug development, reshaping the way therapies are discovered and brought to market.
The global AI in Drug Discovery Market is projected to reach USD 13.2 billion by 2035, expanding at a strong CAGR of 18.4% from 2025 to 2035. Growth is being driven by increasing pharmaceutical and biotechnology R&D investments, rising demand for personalized medicine, and the widespread adoption of AI-powered platforms to identify novel drug candidates and biomarkers. The integration of artificial intelligence into drug discovery is enabling faster, more cost-efficient, and precise development of therapies across oncology, neurology, infectious diseases, and rare genetic disorders, positioning AI as a transformative force in the future of pharmaceutical innovation.
